Silexion Therapeutics announces results from preclinical study of SIL204

Silexion Therapeutics (SLXN) announced new positive preclinical data demonstrating SIL204’s significant efficacy in human lung cancer cell lines. The Company is also pleased to announce that it is in the process of conducting a new study examining the efficacy of SIL204 on a new previously untested KRAS mutation, the results of which it plans to release shortly. If positive, such results could further help establish SIL204 as a potential pan-KRAS treatment. In parallel, Silexion’s dual-route administration strategy, leveraging both intratumoral and systemic delivery approaches, remains on track. The Company continues to prepare for the initiation of a Phase 2/3 clinical trial in Q2 2026 to investigate SIL204 for the treatment of KRAS-driven solid tumor cancers. The study revealed significant dose-dependent inhibition in lung cancer cells harboring KRAS G12D mutations, with notable efficacy, highlighting SIL204’s potential as a versatile therapeutic for lung cancer. The results also support Silexion’s lipid-conjugated delivery system for enhancing SIL204 drug entrance into tumor cells; overcoming a known barrier for siRNA technology and one which is critical for therapeutic efficacy in solid tumors. In May 2025, Silexion announced the completion of initial studies exploring SIL204’s potential impact on colorectal and lung cancer, noting plans to conduct additional studies on lung cancer cell lines in the coming weeks. Today’s announcement fulfills that commitment, providing further validation of SIL204’s mechanism of action and broad potential across multiple KRAS-driven cancer types. These new results provide further validation for Silexion’s innovative approach to KRAS-targeting through RNA interference. Unlike small molecule inhibitors that target already-produced mutant KRAS proteins, SIL204 is designed to silence the production of oncogenic KRAS at the genetic level, preventing the production of these cancer-driving proteins at their source.